Gene single nucleotide polymorphisms (SNPs) have been extensively studied in association with development and prognosis of various malignancies. However, the potential role of genetic polymorphisms of cancer stem cell (CSC) marker genes with respect to cancer risk has not been examined. We conducted a case-control study involving a total of 1000 subjects (500 lung cancer patients and 500 age-matched cancer-free controls) from northeastern China. Lung cancer risk was analyzed in a logistic regression model in association with genotypes of four lung CSC marker genes (CD133, ALDH1, Musashi-1, and EpCAM). Using univariate analysis, the Musashi-1 rs2522137 GG genotype was found to be associated with a higher incidence of lung cancer compared with the TT genotype. No significant associations were observed for gene variants of CD133, ALDH1, or EpCAM. In multivariate analysis, Musashi-1 rs2522137 was still significantly associated with lung cancer when environmental and lifestyle factors were incorporated in the model, including lower BMI; family history of cancer; prior diagnosis of chronic obstructive pulmonary disease, pneumonia, or pulmonary tuberculosis; occupational exposure to pesticide; occupational exposure to gasoline or diesel fuel; heavier smoking; and exposure to heavy cooking emissions. The value of the area under the receiver-operating characteristic (ROC) curve (AUC) was 0.7686. To our knowledge, this is the first report to show an association between a Musashi-1 genotype and lung cancer risk. Further, the prediction model in this study may be useful in determining individuals with high risk of lung cancer.
References
[1]
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300. doi: 10.3322/caac.20073
[2]
Soltanian S, Matin MM (2011) Cancer stem cells and cancer therapy. Tumour Biol 32: 425–440. doi: 10.1007/s13277-011-0155-8
[3]
Kemper K, Grandela C, Medema JP (2010) Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 1: 387–395.
[4]
Keysar SB, Jimeno A (2010) More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 9: 2450–2457. doi: 10.1158/1535-7163.mct-10-0530
[5]
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111. doi: 10.1038/35102167
[6]
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983–3988. doi: 10.1073/pnas.0530291100
[7]
Clarke MF (2005) A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 56 Suppl 164–68. doi: 10.1007/s00280-005-0097-1
[8]
Soltysova A, Altanerova V, Altaner C (2005) Cancer stem cells. Neoplasma 52: 435–440.
[9]
Ratajczak MZ (2005) Cancer stem cells—normal stem cells "Jedi" that went over to the "dark side". Folia Histochem Cytobiol 43: 175–181.
[10]
Sales KM, Winslet MC, Seifalian AM (2007) Stem cells and cancer: an overview. Stem Cell Rev 3: 249–255. doi: 10.1007/s12015-007-9002-0
[11]
Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, et al. (2008) CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8: 784–804. doi: 10.2174/156652408786733667
[12]
Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, et al. (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148: 259–272. doi: 10.1016/j.cell.2011.11.050
[13]
Meng X, Wang Y, Zheng X, Liu C, Su B, et al. (2012) shRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis. Lung Cancer 77: 24–30. doi: 10.1016/j.lungcan.2012.02.015
[14]
Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, et al. (2012) Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 77: 162–167. doi: 10.1016/j.lungcan.2012.02.006
[15]
Kimura M, Takenobu H, Akita N, Nakazawa A, Ochiai H, et al. (2011) Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells. Cancer Sci 102: 983–990. doi: 10.1111/j.1349-7006.2011.01891.x
[16]
Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, et al. (2013) Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8: e54193. doi: 10.1371/journal.pone.0054193
[17]
Moreira AL, Gonen M, Rekhtman N, Downey RJ (2010) Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol 23: 889–895. doi: 10.1038/modpathol.2010.68
[18]
Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, et al. (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94: 128–135.
[19]
Kim Y, Kim HS, Cui ZY, Lee HS, Ahn JS, et al. (2009) Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res 29: 1817–1822.
[20]
van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, et al. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913–1921. doi: 10.1093/carcin/bgq187
[21]
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, et al. (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013–5021.
[22]
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002–5012.
[23]
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504–514. doi: 10.1038/sj.cdd.4402283
[24]
Okano H, Kawahara H, Toriya M, Nakao K, Shibata S, et al. (2005) Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res 306: 349–356. doi: 10.1016/j.yexcr.2005.02.021
[25]
Okano H, Imai T, Okabe M (2002) Musashi: a translational regulator of cell fate. J Cell Sci 115: 1355–1359.
[26]
Kaneko Y, Sakakibara S, Imai T, Suzuki A, Nakamura Y, et al. (2000) Musashi1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev Neurosci 22: 139–153. doi: 10.1159/000017435
[27]
Kanemura Y, Mori K, Sakakibara S, Fujikawa H, Hayashi H, et al. (2001) Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 68: 141–152. doi: 10.1046/j.1432-0436.2001.680208.x
[28]
Wang T, Ong CW, Shi J, Srivastava S, Yan B, et al. (2011) Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer 105: 658–665.
[29]
Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, et al. (2010) Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis 25: 17–23. doi: 10.1007/s00384-009-0791-2
[30]
Shu HJ, Saito T, Watanabe H, Ito JI, Takeda H, et al. (2002) Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines. Biochem Biophys Res Commun 293: 150–154. doi: 10.1016/s0006-291x(02)00175-4
[31]
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555–567. doi: 10.1016/j.stem.2007.08.014
[32]
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, et al. (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330–338. doi: 10.1158/1541-7786.mcr-08-0393
[33]
Liang D, Shi Y (2012) Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Med Oncol 29: 633–639. doi: 10.1007/s12032-011-9933-9
[34]
Serrano D, Bleau AM, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, et al. (2011) Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer 10: 96. doi: 10.1186/1476-4598-10-96
[35]
Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, et al. (1997) Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139: 1337–1348. doi: 10.1083/jcb.139.5.1337
[36]
Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, et al. (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23: 5748–5758. doi: 10.1038/sj.onc.1207610
[37]
Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, et al. (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818–5824. doi: 10.1158/0008-5472.can-04-0754
[38]
Amos W, Driscoll E, Hoffman JI (2011) Candidate genes versus genome-wide associations: which are better for detecting genetic susceptibility to infectious disease? Proc Biol Sci 278: 1183–1188. doi: 10.1098/rspb.2010.1920
[39]
Clark AG (2004) The role of haplotypes in candidate gene studies. Genet Epidemiol 27: 321–333. doi: 10.1002/gepi.20025
[40]
Leng S, Stidley CA, Liu Y, Edlund CK, Willink RP, et al. (2012) Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study. Cancer Res 72: 707–715. doi: 10.1158/0008-5472.can-11-3194
[41]
Eramo A, Haas TL, De Maria R (2010) Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29: 4625–4635. doi: 10.1038/onc.2010.207
[42]
Koren A, Motaln H, Cufer T (2013) Lung cancer stem cells: a biological and clinical perspective. Cell Oncol (Dordr) 36: 265–275. doi: 10.1007/s13402-013-0141-9
[43]
Siddall NA, McLaughlin EA, Marriner NL, Hime GR (2006) The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. Proc Natl Acad Sci U S A 103: 8402–8407. doi: 10.1073/pnas.0600906103
[44]
Sakakibara S, Imai T, Hamaguchi K, Okabe M, Aruga J, et al. (1996) Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol 176: 230–242. doi: 10.1006/dbio.1996.0130
[45]
Nishimura S, Wakabayashi N, Toyoda K, Kashima K, Mitsufuji S (2003) Expression of Musashi-1 in human normal colon crypt cells: a possible stem cell marker of human colon epithelium. Dig Dis Sci 48: 1523–1529.
[46]
Vo DT, Qiao M, Smith AD, Burns SC, Brenner AJ, et al. (2011) The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol 8: 817–828. doi: 10.4161/rna.8.5.16041
[47]
Vo DT, Abdelmohsen K, Martindale JL, Qiao M, Tominaga K, et al. (2012) The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res 10: 143–155. doi: 10.1158/1541-7786.mcr-11-0208
[48]
Barreau C, Paillard L, Osborne HB (2005) AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 33: 7138–7150. doi: 10.1093/nar/gki1012
[49]
Abdelmohsen K, Gorospe M (2010) Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 1: 214–229. doi: 10.1002/wrna.4
[50]
Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, et al. (2009) Lung cancer susceptibility model based on age, family history and genetic variants. PLOS One 4: e5302. doi: 10.1371/journal.pone.0005302
[51]
Young RP, Hopkins RJ, Whittington CF, Hay BA, Epton MJ, et al. (2011) Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD. PLOS One 6: e16476. doi: 10.1371/journal.pone.0016476
[52]
Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, et al. (2008) The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 98: 270–276.
[53]
Raji OY, Agbaje OF, Duffy SW, Cassidy A, Field JK (2010) Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: the Liverpool Lung Project. Cancer Prev Res (Phila) 3: 664–669. doi: 10.1158/1940-6207.capr-09-0141
[54]
Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, et al. (2011) Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 17: 6934–6943. doi: 10.1158/1078-0432.ccr-11-1180
